Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $43.60 Consensus Price Target from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $38.00.

Several research analysts recently commented on INO shares. Royal Bank of Canada reduced their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 15th. Oppenheimer reduced their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, November 18th. Finally, HC Wainwright lowered their target price on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Monday, November 18th.

Inovio Pharmaceuticals Trading Up 0.2 %

Shares of INO stock opened at $4.07 on Friday. Inovio Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $14.75. The stock has a 50 day moving average of $5.50 and a two-hundred day moving average of $7.92.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in Inovio Pharmaceuticals during the second quarter worth about $661,000. Signature Estate & Investment Advisors LLC bought a new stake in Inovio Pharmaceuticals during the 2nd quarter worth approximately $88,000. Rhumbline Advisers increased its holdings in Inovio Pharmaceuticals by 5,943.0% during the 2nd quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 37,857 shares in the last quarter. American Century Companies Inc. raised its position in Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 12,100 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in Inovio Pharmaceuticals in the second quarter worth $184,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.